The Journal of Nutritional Biochemistry
Volume 21, Issue 7 , Pages 621-626 , July 2010

Peroxisome proliferator-activated receptors γ and α agonists stimulate cardiac glucose uptake via activation of AMP-activated protein kinase

  • Xiaoyan Xiao

      Affiliations

    • Department of Endocrinology, Qilu Hospital, Shandong University, Jinan 250012, P.R. China
    • These two authors contributed equally to this work.
    • ,
  • Guohai Su

      Affiliations

    • Department of Cardiology, Jinan Central Hospital, Shandong University, Jinan 250013, P.R. China
    • These two authors contributed equally to this work.
    • ,
  • Stacey N. Brown

      Affiliations

    • Section of Endocrinology, Department of Internal Medicine, School of Medicine, Yale University, New Haven, CT 06520, USA
    • ,
  • Li Chen

      Affiliations

    • Department of Endocrinology, Qilu Hospital, Shandong University, Jinan 250012, P.R. China
    • ,
  • Jianmin Ren

      Affiliations

    • Department of Endocrinology, Qilu Hospital, Shandong University, Jinan 250012, P.R. China
    • ,
  • Peng Zhao

      Affiliations

    • Department of Cardiology, Shandong Provincial Hospital, Shandong University, Jinan 250021, P.R. China
    • Corresponding Author InformationCorresponding author. Tel.: +86 011 531 85186416; fax: +86 011 531 85186306.

Received 8 October 2008 ,Revised 9 March 2009 ,Accepted 10 March 2009.

References 

  1. Marx N, Duez H, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells. Circ Res. 2004;94:1168–1178
  2. Zahradka P, Wright B, Fuerst M, Yurkova N, Molnar K, Taylor CG. Peroxisome proliferator-activated receptor alpha and gamma ligands differentially affect smooth muscle cell proliferation and migration. J Pharmacol Exp Ther. 2006;317:651–659
  3. Diep QN, Amiri F, Touyz RM, Cohn JS, Endemann D, Neves MF, et al. PPARalpha activator effects on Ang II-induced vascular oxidative stress and inflammation. Hypertension. 2002;40:866–871
  4. Tao L, Liu HR, Gao E, Teng ZP, Lopez BL, Christopher TA, et al. Antioxidative, antinitrative, and vasculoprotective effects of a peroxisome proliferator-activated receptor-gamma agonist in hypercholesterolemia. Circulation. 2003;108:2805–2811
  5. Delerive P, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors in inflammation control. J Endocrinol. 2001;169:453–459
  6. Tontonoz P, Hu E, Spiegelman BM. Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell. 1994;79:1147–1156
  7. Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev. 1999;20:649–688
  8. Seimandi M, Lemaire G, Pillon A, Perrin A, Carlavan I, Voegel JJ, et al. Differential responses of PPARalpha, PPARdelta, and PPARgamma reporter cell lines to selective PPAR synthetic ligands. Anal Biochem. 2005;344:8–15
  9. Zingarelli B, Hake PW, Mangeshkar P, O'Connor M, Burroughs TJ, Piraino G, et al. Diverse cardioprotective signaling mechanisms of peroxisome proliferator-activated receptor-gamma ligands, 15-deoxy-Delta12,14-prostaglandin J2 and ciglitazone, in reperfusion injury: role of nuclear factor-kappaB, heat shock factor 1, and Akt. Shock. 2007;28:554–563
  10. Mersmann J, Tran N, Zacharowski PA, Grotemeyer D, Zacharowski K. Rosiglitazone is cardioprotective in a murine model of myocardial I/R. Shock. 2008;30:64–68
  11. Li D, Chen K, Sinha N, Zhang X, Wang Y, Sinha AK, et al. The effects of PPAR-gamma ligand pioglitazone on platelet aggregation and arterial thrombus formation. Cardiovasc Res. 2005;65:907–912
  12. Wayman NS, Hattori Y, McDonald MC, Mota-Filipe H, Cuzzocrea S, Pisano B, et al. Ligands of the peroxisome proliferator-activated receptors (PPAR-gamma and PPAR-alpha) reduce myocardial infarct size. FASEB J. 2002;16:1027–1040
  13. Ishibashi M, Egashira K, Hiasa K, Inoue S, Ni W, Zhao Q, et al. Antiinflammatory and antiarteriosclerotic effects of pioglitazone. Hypertension. 2002;40:687–693
  14. Ito H, Nakano A, Kinoshita M, Matsumori A. Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates myocardial ischemia/reperfusion injury in a rat model. Lab Invest. 2003;83:1715–1721
  15. Yue Tl TL, Chen J, Bao W, Narayanan PK, Bril A, Jiang W, et al. In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. Circulation. 2001;104:2588–2594
  16. Honda T, Kaikita K, Tsujita K, Hayasaki T, Matsukawa M, Fuchigami S, et al. Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates myocardial ischemia-reperfusion injury in mice with metabolic disorders. J Mol Cell Cardiol. 2008;44:915–926
  17. Kudo N, Barr AJ, Barr RL, Desai S, Lopaschuk GD. High rates of fatty acid oxidation during reperfusion of ischemic hearts are associated with a decrease in malonyl-CoA levels due to an increase in 5′-AMP-activated protein kinase inhibition of acetyl-CoA carboxylase. J Biol Chem. 1995;270:17513–17520
  18. Winder WW, Hardie DG. Inactivation of acetyl-CoA carboxylase and activation of AMP-activated protein kinase in muscle during exercise. Am J Physiol. 1996;270:E299–E304
  19. Barnes BR, Zierath JR. Role of AMP-activated protein kinase in the control of glucose homeostasis. Curr Mol Med. 2005;5:341–348
  20. Hardie DG. The AMP-activated protein kinase pathway — new players upstream and downstream. J Cell Sci. 2004;117:5479–5487
  21. Mu J, Brozinick JT, Valladares O, Bucan M, Birnbaum MJ. A role for AMP-activated protein kinase in contraction- and hypoxia-regulated glucose transport in skeletal muscle. Mol Cell. 2001;7:1085–1094
  22. Russell RR, Li J, Coven DL, Pypaert M, Zechner C, Palmeri M, et al. AMP-activated protein kinase mediates ischemic glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and injury. J Clin Invest. 2004;114:495–503
  23. Xing Y, Musi N, Fujii N, Zou L, Luptak I, Hirshman MF, et al. Glucose metabolism and energy homeostasis in mouse hearts overexpressing dominant negative alpha2 subunit of AMP-activated protein kinase. J Biol Chem. 2003;278:28372–28377
  24. Li J, Hu X, Selvakumar P, Russell RR, Cushman SW, Holman GD, et al. Role of the nitric oxide pathway in AMPK-mediated glucose uptake and GLUT4 translocation in heart muscle. Am J Physiol Endocrinol Metab. 2004;287:E834–E841
  25. Fryer LG, Hajduch E, Rencurel F, Salt IP, Hundal HS, Hardie DG, et al. Activation of glucose transport by AMP-activated protein kinase via stimulation of nitric oxide synthase. Diabetes. 2000;49:1978–1985
  26. Morrow VA, Foufelle F, Connell JM, Petrie JR, Gould GW, Salt IP. Direct activation of AMP-activated protein kinase stimulates nitric-oxide synthesis in human aortic endothelial cells. J Biol Chem. 2003;278:31629–31639
  27. Vicent D, Ilany J, Kondo T, Naruse K, Fisher SJ, Kisanuki YY, et al. The role of endothelial insulin signaling in the regulation of vascular tone and insulin resistance. J Clin Invest. 2003;111:1373–1380
  28. Ceolotto G, Gallo A, Papparella I, Franco L, Murphy E, Iori E, et al. Rosiglitazone reduces glucose-induced oxidative stress mediated by NAD(P)H oxidase via AMPK-dependent mechanism. Arterioscler Thromb Vasc Biol. 2007;27:2627–2633
  29. Murakami H, Murakami R, Kambe F, Cao X, Takahashi R, Asai T, et al. Fenofibrate activates AMPK and increases eNOS phosphorylation in HUVEC. Biochem Biophys Res Commun. 2006;341:973–978
  30. Ryu JH, Cho YS, Chun YS, Park JW. Myocardial SSAT induction via AMPK signaling and its implication for ischemic injury. Biochem Biophys Res Commun. 2008;366:438–444
  31. Ebrahimi F, Hajrasouliha AR, Tavakoli S, Sadeghipour H, Ghasemi M, Rofoui BR, et al. Pentoxifylline improves reoxygenation-induced contractile recovery through a nitric oxide-dependent mechanism in rat papillary muscles. J Cardiovasc Pharmacol. 2006;47:571–577
  32. Russell RR, Bergeron R, Shulman GI, Young LH. Translocation of myocardial GLUT-4 and increased glucose uptake through activation of AMPK by AICAR. Am J Physiol. 1999;277:H643–H649
  33. Manfredi G, Yang L, Gajewski CD, Mattiazzi M. Measurements of ATP in mammalian cells. Methods. 2002;26:317–326
  34. Fediuc S, Pimenta AS, Gaidhu MP, Ceddia RB. Activation of AMP-activated protein kinase, inhibition of pyruvate dehydrogenase activity, and redistribution of substrate partitioning mediate the acute insulin-sensitizing effects of troglitazone in skeletal muscle cells. J Cell Physiol. 2008;215:392–400
  35. LeBrasseur NK, Kelly M, Tsao TS, Farmer SR, Saha AK, Ruderman NB, et al. Thiazolidinediones can rapidly activate AMP-activated protein kinase in mammalian tissues. Am J Physiol Endocrinol Metab. 2006;291:E175–E181
  36. van Bilsen M, Smeets PJ, Gilde AJ, van der Vusse GJ. Metabolic remodelling of the failing heart: the cardiac burn-out syndrome?. Cardiovasc Res. 2004;61:218–226
  37. Viollet B, Mounier R, Leclerc J, Yazigi A, Foretz M, Andreelli F. Targeting AMP-activated protein kinase as a novel therapeutic approach for the treatment of metabolic disorders. Diabetes Metab. 2007;33:395–402
  38. Carvajal K, Zarrinpashneh E, Szarszoi O, Joubert F, Athea Y, Mateo P, et al. Dual cardiac contractile effects of the alpha2-AMPK deletion in low-flow ischemia and reperfusion. Am J Physiol Heart Circ Physiol. 2007;292:H3136–H3147
  39. Pershadsingh HA. Treating the metabolic syndrome using angiotensin receptor antagonists that selectively modulate peroxisome proliferator-activated receptor-gamma. Int J Biochem Cell Biol. 2006;38:766–781
  40. Okayasu T, Tomizawa A, Suzuki K, Manaka K, Hattori Y. PPARalpha activators upregulate eNOS activity and inhibit cytokine-induced NF-kappaB activation through AMP-activated protein kinase activation. Life Sci. 2008;82:884–891
  41. Tada H, Thompson CI, Recchia FA, Loke KE, Ochoa M, Smith CJ, et al. Myocardial glucose uptake is regulated by nitric oxide via endothelial nitric oxide synthase in Langendorff mouse heart. Circ Res. 2000;86:270–274
  42. Balon TW, Nadler JL. Nitric oxide mediates skeletal glucose transport. Am J Physiol. 1996;270:E1058–E1059
  43. Shiono N, Rao V, Weisel RD, Kawasaki M, Li RK, Mickle DA, et al. l-Arginine protects human heart cells from low-volume anoxia and reoxygenation. Am J Physiol Heart Circ Physiol. 2002;282:H805–H815
  44. Gonon AT, Bulhak A, Labruto F, Sjoquist PO, Pernow J. Cardioprotection mediated by rosiglitazone, a peroxisome proliferator-activated receptor gamma ligand, in relation to nitric oxide. Basic Res Cardiol. 2007;102:80–89

☆ Support: This work was supported in part by the Natural Science Foundation of Shandong Province (#Y2002C47), Jinan Rising-Star Program (#07112) and Key Technologies R & D Program of Jinan, Shandong Province, China (#200705089-4).

PII: S0955-2863(09)00078-3

doi: 10.1016/j.jnutbio.2009.03.011

The Journal of Nutritional Biochemistry
Volume 21, Issue 7 , Pages 621-626 , July 2010

Article Tools

* Image Usage & Resolution